HomeComparePTKFY vs PLD

PTKFY vs PLD: Dividend Comparison 2026

PTKFY yields 4.06% · PLD yields 3.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PLD wins by $5.87M in total portfolio value
10 years
PTKFY
PTKFY
● Live price
4.06%
Share price
$10.88
Annual div
$0.44
5Y div CAGR
19.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$41.6K
Annual income
$4,502.78
Full PTKFY calculator →
PLD
PLD
● Live price
3.10%
Share price
$132.18
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.91M
Annual income
$4,750,725.19
Full PLD calculator →

Portfolio growth — PTKFY vs PLD

📍 PLD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPTKFYPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PTKFY + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PTKFY pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PTKFY
Annual income on $10K today (after 15% tax)
$345.04/yr
After 10yr DRIP, annual income (after tax)
$3,827.36/yr
PLD
Annual income on $10K today (after 15% tax)
$263.66/yr
After 10yr DRIP, annual income (after tax)
$4,038,116.41/yr
At 15% tax rate, PLD beats the other by $4,034,289.05/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PTKFY + PLD for your $10,000?

PTKFY: 50%PLD: 50%
100% PLD50/50100% PTKFY
Portfolio after 10yr
$2.97M
Annual income
$2,377,613.98/yr
Blended yield
79.92%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

PTKFY
No analyst data
Altman Z
3.3
Piotroski
6/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+2.9% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PTKFY buys
0
PLD buys
0
No recent congressional trades found for PTKFY or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPTKFYPLD
Forward yield4.06%3.10%
Annual dividend / share$0.44$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR19.4%74.4%
Portfolio after 10y$41.6K$5.91M
Annual income after 10y$4,502.78$4,750,725.19
Total dividends collected$18.1K$5.78M
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: PTKFY vs PLD ($10,000, DRIP)

YearPTKFY PortfolioPTKFY Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$11,185$484.68$11,241$540.96$56.00PLD
2$12,573$604.92$13,019$991.13$446.00PLD
3$14,211$758.78$15,801$1,870.97$1.6KPLD
4$16,163$957.09$20,609$3,701.21$4.4KPLD
5$18,509$1,214.69$29,919$7,867.97$11.4KPLD
6$21,357$1,552.20$50,631$18,617.74$29.3KPLD
7$24,851$1,998.58$105,528$51,352.20$80.7KPLD
8$29,185$2,595.01$287,364$174,449.42$258.2KPLD
9$34,629$3,400.82$1,081,760$774,280.77$1.05MPLD
10$41,556$4,502.78$5,908,209$4,750,725.19$5.87MPLD

PTKFY vs PLD: Complete Analysis 2026

PTKFYStock

PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. The company operates through four divisions: Prescription Pharmaceuticals, Consumer Health, Nutritionals, and Distribution and Logistic. It offers generic, branded, and licensed drugs, including Brainact, Cefspan, Mycoral, Cernevit, Cravit, Neuralgin, Broadced, Neurotam, Hemapo, and CPG that are distributed to hospitals, pharmacies, and drug stores. The company also provides over-the-counter drugs; energy drinks, ready-to-drink products, supplements, and other preventive products; and nutritional products for infants, toddlers, children, teenagers, adults, pregnant and lactating women, and elders, as well as for consumers with special medical needs. In addition, it offers contract services, including clinical study management, bioavailability/bioequivalence studies, and contract analysis to pharmaceutical companies; and animal health products, as well as operates Mitrasana Clinics, a health care service. Further, the company provides health screening services; operates as an agent and representative for biotechnology products; distributes consumer products, medical equipment, cosmetics, and other trading products; and trades in medical and laboratory equipment and supplies, raw materials for pharmaceutical products, and consumable products for hemodialysis therapy, as well as offers advertising services. PT Kalbe Farma Tbk. was incorporated in 1966 and is headquartered in Jakarta, Indonesia.

Full PTKFY Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this PTKFY vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PTKFY vs SCHDPTKFY vs JEPIPTKFY vs OPTKFY vs KOPTKFY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.